Continue to Site

Pemazyre offers promise for cholangiocarcinoma

By Brian Buntz | July 21, 2021

Pemazyre (pemigatinib) from Innovent Biologics is a novel treatment for cholangiocarcinoma, a type of bile duct cancer. The indication covers unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Innovent continues to roll the drug out throughout the world. In June, it won regulatory approval in Taiwan to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. That approval also refers to cholangiocarcinoma with a FGFR2 fusion or rearrangement

Filed Under: Oncology
Tagged With: bile duct cancer, cholangiocarcinoma, fibroblast growth factor receptor 2, Innovent Biologics, Pemazyre

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.